Manifestation of cognitive impairment in both Patients 4 and 5, in spite of non-overlapping deletions, suggests that two dosage sensitive genes, within SRO I and II, independently contribute to cognitive impairment when deleted. The gene discussed is STOML3; the disease is Cognitive impairment.